Literature DB >> 8549684

Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism.

N P Chanaud1, B P Vistica, E Eugui, R B Nussenblatt, A C Allison, I Gery.   

Abstract

Mycophenolate mofetil (MM), an inhibitor of purine metabolism, was found to effectively inhibit the development of experimental autoimmune uveoretinitis (EAU) induced by S-antigen (SAg) in Lewis rats. MM completely inhibited EAU development in the majority of rats when administered daily, on days 0-13, at a dose of 30 mg kg-1 day-1. The drug was less effective, however, when given on days 7-20: minimal disease inhibition was achieved with the drug at 30 mg kg-1 day-1, although at 60 mg kg-1 day-1 the drug inhibited EAU development in most treated rats during the period of its administration. MM also completely inhibited in most treated rats the development of EAU adoptively transferred by SAg-sensitized lymphocytes, thus depicting its capacity to inhibit the efferent limb of the immune response. Treatment with MM also suppressed the cellular and humoral immune responses against SAg, with a good correlation being observed between the inhibition of these responses and suppression of EAU in the different groups of rats. MM is currently being examined for its immunosuppressive effects in humans and the data recorded here thus suggest this compound may be useful in treatment of immune-mediated uveitic conditions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549684     DOI: 10.1016/s0014-4835(05)80138-1

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  12 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 2.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 3.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

4.  Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.

Authors:  C A Jonsson; L Svensson; H Carlsten
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

5.  Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients.

Authors:  Kirsten Siepmann; Matthias Huber; Nicole Stübiger; Christoph Deuter; Manfred Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-15       Impact factor: 3.117

6.  Effects of mycophenolate mofetil on proliferation and mucin-5AC expression in human conjunctival goblet cells in vitro.

Authors:  Hong He; Hui Ding; Aiping Liao; Qiong Liu; Jun Yang; Xingwu Zhong
Journal:  Mol Vis       Date:  2010-10-01       Impact factor: 2.367

7.  Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits.

Authors:  Fabio Gasparin; Renata Genaro Aguiar; Gabriela Lourençon Ioshimoto; Armando Silva-Cunha; Silvia Ligório Fialho; André Mauricio Liber; Balázs Vince Nagy; Nestor Norio Oiwa; Marcelo Fernandes Costa; Christina Joselevitch; Dora Fix Ventura; Francisco Max Damico
Journal:  J Ocul Pharmacol Ther       Date:  2014-05-14       Impact factor: 2.671

8.  Mycophenolate mofetil therapy in uveitis: analysis of eight cases in a tertiary ophthalmic care centre in India.

Authors:  Vishal M Rathore; Rupesh Agrawal; S P Chaudhary; Jyotirmay Biswas
Journal:  Int Ophthalmol       Date:  2007-12-13       Impact factor: 2.031

Review 9.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

Review 10.  Systemic therapies for inflammatory eye disease: past, present and future.

Authors:  Alastair K Denniston; Andrew D Dick
Journal:  BMC Ophthalmol       Date:  2013-04-24       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.